Principal Investigators

    Professor S Lovestone


    University of Oxford

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    WNT signaling: biomarker and target evaluation in Alzheimer's disease

    Source of funding information


    Total sum awarded (Euro)

    € 298,443

    Start date of award


    Total duration of award in years



    Research Abstract

    The consistent failure of biopharmaceutical pipelines to modify Alzheimer’s disease progression indicates a need for new and creative solutions. In this project we will explore elements of the canonical (WNT/GSK3) and non-canonical (WNT/JNK) signaling pathways as novel targets that could be used to monitor and modify Alzheimer’s progression. Our teams are applying a multidisciplinary approach that combines brain-oriented drug screening, new genetic and pharmacological tools, new animal models and human blood and cerebrospinal fluid samples, which, together, explore the impact on AD of novel WNT elements, including but not limited to the apolipoprotein clusterin, the WNT inhibitor DKK1 and the transcription factor Nrf2.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF